Minerva Neurosciences (NERV)
(Delayed Data from NSDQ)
$2.63 USD
+0.04 (1.54%)
Updated Aug 23, 2024 03:06 PM ET
After-Market: $2.64 +0.01 (0.38%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Brokerage Reports
Minerva Neurosciences, Inc [NERV]
Reports for Purchase
Showing records 21 - 40 ( 43 total )
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Monetization of Seltorexant Should Allow Minerva to Capture Roluperidone?s Full Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
FDA Likes Roluperidone, But Has Issues With the Current Data Package; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
FDA Meeting Expected to Provide Clarity on Roluperidone?s Path Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Minerva Schedules FDA Meeting Regarding Roluperidone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Upcoming FDA Meeting Should Provide Visibility for Roluperidone?s Path; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Minerva Opts out of Seltorexant Agreement With Janssen to Focus on Roluperidone
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
We Still Like Roluperidone After Another Look at the Data; Reiterate Buy, Target to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Quick Thoughts After Roluperidone Misses Primary Endpoint in Phase 3
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
No News Is Good News as Roluperidone Phase 3 Readout Rapidly Approaches; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Don''t Sleep on New Mechanisms for MDD: A Look at GABA Modulation and Orexin-2 Antagonists
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
KOLs Highlight Roluperidone as Potential Game Changer; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
KOLs Highlight Broader Opportunity for Roluperidone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
MIN-117 Fails Short, But It Wasn''t Central to Our Thesis; Tweak Target Down to $20, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Perspectives from KOL Dinner on Major Depressive Disorder
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Key Catalysts Upcoming for a Pipeline With Differentiated Assets; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Missing the Forest for the Trees as Seltorexant Shines Again; Reiterate Buy and $22 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Minerva Neurosciences, Inc
Industry: Medical - Drugs
Plentiful Catalysts Into Year-End Make it Hard to Ignore; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D